Notch1 Antibody Monoclonal

Product Description

Notch1 Antibody Monoclonal
Catalog number: B2010598
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 200 uL
Molecular Weight or Concentration: na
Supplied as: Solution
Applications: molecular tool in the study of Notch 1
Storage: -20C
Keywords: Notch antibody, anti-notch1 antibody
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Wieland E, Rodriguez-Vita J, Liebler SS, Mogler C, Moll I, Herberich SE,
Espinet E, Herpel E, Menuchin A, Chang-Claude J, Hoffmeister M, Gebhardt C,
Brenner H, Trumpp A, Siebel CW, Hecker M, Utikal J, Sprinzak D, Fischer A.
Endothelial Notch1 Activity Facilitates Metastasis. Cancer Cell. 2017 Mar
13;31(3):355-367.

2: Gharaibeh L, Elmadany N, Alwosaibai K, Alshaer W. Notch1 in Cancer Therapy:
Possible Clinical Implications and Challenges. Mol Pharmacol. 2020
Nov;98(5):559-576.

3: López-Guerra M, Xargay-Torrent S, Fuentes P, Roldán J, González-Farré B,
Rosich L, Silkenstedt E, García-León MJ, Lee-Vergés E, Giménez N, Giró A,
Aymerich M, Villamor N, Delgado J, López-Guillermo A, Puente XS, Campo E,
Toribio ML, Colomer D. Specific NOTCH1 antibody targets DLL4-induced
proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells.
Oncogene. 2020 Feb;39(6):1185-1197.

4: Katoh M, Katoh M. Precision medicine for human cancers with Notch signaling
dysregulation (Review). Int J Mol Med. 2020 Feb;45(2):279-297.
5: Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J
Hematol. 2016 Mar;91(3):330-40.

6: Tyagi A, Sharma AK, Damodaran C. A Review on Notch Signaling and Colorectal
Cancer. Cells. 2020 Jun 25;9(6):1549.

7: Silkenstedt E, Arenas F, Colom-Sanmartí B, Xargay-Torrent S, Higashi M, Giró
A, Rodriguez V, Fuentes P, Aulitzky WE, van der Kuip H, Beà S, Toribio ML, Campo
E, López-Guerra M, Colomer D. Notch1 signaling in NOTCH1-mutated mantle cell
lymphoma depends on Delta-Like ligand 4 and is a potential target for specific
antibody therapy. J Exp Clin Cancer Res. 2019 Nov 1;38(1):446.

8: Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D’Rozario J, Assouline S,
Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J,
Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose
E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour
JF. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year
Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From
the MURANO Phase III Study. J Clin Oncol. 2020 Dec 1;38(34):4042-4054.

9: Zhu G, Wang X, Xiao H, Liu X, Fang Y, Zhai B, Xu R, Han G, Chen G, Hou C,
Shen B, Li Y, Ma N, Wu H, Liu G, Wang R. Both Notch1 and its ligands in B cells
promote antibody production. Mol Immunol. 2017 Nov;91:17-23.
10: Ahmed AA, Robinson T, Palande M, Escara-Wilke J, Dai J, Keller ET. Targeted
Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in
two murine models of prostate cancer in association with differing patterns of
DNA damage response gene expression. J Cell Biochem. 2019
Oct;120(10):16946-16955.

Products Related to Notch1 Antibody Monoclonal: Antibodies